Follicular helper T cells (T FH cells) are CD4 + T cells specialized in helping B cells and are associated both with protective antibody responses and autoimmune diseases. The promise of targeting T FH cells therapeutically has been limited by fragmentary understanding of extrinsic signals that regulate the differentiation of human T FH cells. A screen of a human protein library identified activin A as a potent regulator of T FH cell differentiation. Activin A orchestrated the expression of multiple genes associated with the T FH program, independently or in concert with additional signals. T FH cell programming by activin A was antagonized by the cytokine IL-2. Activin A's ability to drive T FH cell differentiation in vitro was conserved in non-human primates but not in mice. Finally, activin-A-induced T FH programming was dependent on signaling via SMAD2 and SMAD3 and was blocked by pharmacological inhibitors.
Antibody responses are a powerful arm of the adaptive immune system for preventing and fighting pathogen infection. To produce antibodies with high affinity and pathogen-neutralization potential, naive B cells are activated and divide in response to cognate antigen and subsequently undergo rounds of somatic hypermutation and selection in germinal centers (GCs), which are specialized microanatomical sites in secondary lymphoid organs. This process of affinity maturation is tightly regulated by follicular helper T cells (T FH cells) 1-3 , a distinct subset of CD4 + T cells specialized in helping B cells. T FH cells provide signals for the selection, survival and proliferation of GC B cells via the production of cytokines and expression of costimulatory molecules 4 . The provision of help by T FH cells to B cells has been found to be a limiting factor for determining the magnitude of GC reactions and the mutation rate of GC B cells 1, 5 .
The distinctive features of T FH cells are acquired during a multistage, multi-factorial differentiation process that takes place in secondary lymphoid organs 1, 6, 7 . Upon priming of naive CD4 + T cells by dendritic cells or other myeloid antigen-presenting cells, activated antigen-specific CD4 + T cells can upregulate expression of the chemokine receptor CXCR5 and become early precursors of T FH cells. The activated CXCR5 + CD4 + T cells migrate toward the B cell follicles after downregulating their expression of the chemokine receptor CCR7. At this early stage of differentiation, CXCR5 int CCR7 lo T FH cells can be found at the border between the T cell area and B cell follicles (the T cell-B cell border) and in B cell follicles. Here, T FH cells interact with cognate B cells, which deliver stimuli to T FH cells to complete their differentiation. Fully polarized GC T FH cells are located within GCs and have high expression of CXCR5 (CXCR5 hi ) and Bcl6, the transcription factor that defines the T FH cell lineage 1, 6 . GC T FH cells are functionally mature B cell helpers and are characterized by high expression of canonical functional mediators, including interleukin 21 (IL-21), the chemokine CXCL13, the ligand for the costimulatory receptor CD40, the costimulatory receptor ICOS, the receptor SLAMF1 and IL-4, along with a series of inhibitory receptors (PD-1, BTLA and others), that restrain T FH cells from excessive proliferation 1, 4 .
Multiple signaling pathways act together to 'imprint' the T FH -differentiation program. Over the past decade, roles for ICOS, IL-6, IL-21, IL-2, receptors of the SLAM family and other molecules have been shown to regulate the differentiation of mouse T FH cells 1, 6 . However, few studies have identified regulators of human T FH cell biology. Interestingly, some data have suggested evolutionary divergence between the signaling pathways that shape human T FH cell differentiation and those that shape mouse T FH cell differentiation. IL-6 is the dominant inducer of mouse IL-21 production and is an important early regulator of T FH differentiation in mice [8] [9] [10] [11] , but it has minimal effects on the induction of IL-21 in human CD4 + T cells and the in vitro generation of T FH cells 12 . In contrast, IL-12 is a potent regulator of IL-21 production and T FH differentiation in humans 13, 14 , but it has only a minor effect on the expression of IL-21 by mouse CD4 + T cells 8, 15 . Thus, while they are extremely valuable for studies of evolutionarily shared pathways, mice might represent a limited model for the identification of regulators of human T FH cell differentiation. In light of such apparent differences, we developed an in vitro screen of a large collection of human recombinant proteins to identify previously unknown regulators of human T FH cell differentiation.
RESULTS

Screen for regulators of human T FH cell differentiation
To discover previously unknown regulators of human T FH cell differentiation, we performed an unbiased high-throughput screen of a human extracellular proteome library consisting of over 2,000 human proteins predicted or known to be cytokines, chemokines, morphogens, costimulatory receptors, or single-pass transmembrane molecules 16 . Each unique protein in this proteome ('secretomics') library was produced as a secreted recombinant molecule and was tested for its ability to modulate the differentiation of activated naive CD4 + T cells into T FH cells in vitro (Supplementary Fig. 1a,b) . For this, activated human naive CD4 + T cells were cultured for 5 d in the presence of the human secretome library. Expression of the T FH cell signature markers CXCR5 and PD-1 was measured by flow cytometry, in an automated fashion. The primary screen revealed multiple recombinant proteins that either induced or inhibited the expression of CXCR5 and PD-1, as assessed by the frequency of PD-1 + CXCR5 + cells ( Fig. 1a ) or CXCR5 + cells ( Supplementary Fig. 1c ), ranked by z-score. In the primary screen, we identified 11 members of the type I interferon cytokine family, known inhibitors of the differentiation of mouse T FH cells 17 and human T FH cells 12 , as suppressors of expression of CXCR5 and PD-1 ( Fig. 1a) . Activin A, the inhibin beta A (INHBA) homodimer, emerged as the most potent inducer of the expression of CXCR5 and PD-1 ( Fig. 1a) . We then confirmed the primary screen results and found that activin A induced expression of CXCR5 and PD-1 ( Fig. 1b) .
Activin A belongs to the family of activins and inhibins, a group of five distinct dimeric cytokines that can arise from three monomer subunits: inhibin alpha, inhibin beta A and inhibin beta B 18 . Activin A is a pleiotropic cytokine involved in multiple vital biological processes, including the maintenance of pluripotent stem cells [19] [20] [21] [22] [23] . However, the role of activin A in the immune system is not fully understood, with only a small number of studies providing evidence for the involvement of activin A in T cell biology 22, [24] [25] [26] . We evaluated the presence of activin A in human tonsils, a lymphoid tissue enriched for T FH cells and GCs in which T FH cell differentiation physiologically occurs. INHBA protein was present in T cell zones, including the T cell-B cell borders, of all tonsils analyzed ( Fig. 2a and Supplementary Fig. 2a ). INHBA + T cells were observed ( Fig. 2a) . The greatest INHBA production was in CD3 − cells with myeloid cell morphology ( Fig. 2a) , consistent with the known ability of monocytes, dendritic cells and macrophages to produce activin A [27] [28] [29] . Staining of CD11c revealed both CD11c + cells and CD11c − cells that expressed INHBA in T cell areas ( Fig. 2b and Supplementary Fig. 2b ). Furthermore, blood monocytes upregulated INHBA expression within 4 h of stimulation with lipopolysaccharide and secreted activin A protein ( Fig. 2c,d) , which confirmed that these human antigen-presenting cells were able to produce activin A.
We then validated the role of activin A in in vitro T FH cell differentiation through the use of primary naive CD4 + T cells from human donors ( Fig. 3a-c) and activin A from various commercial vendors (data not shown). Furthermore, we used serum-free medium throughout these validation experiments to rule out the possibility of indirect effects of undefined serum components. In stringent serum-free conditions, activin A induced the expression of both PD-1 and CXCR5 on activated naive CD4 + T cells in a dosedependent fashion (Fig. 3a,b and Supplementary Fig. 3a ), which demonstrated a direct effect of activin A on human T FH cell differentiation. Overall, these data indicated that our screen of human proteins enabled the identification of factors that functioned as early regulators of human T FH cell differentiation, with activin A identified as the 'top hit' in the screen.
Modulation of activin A activity by members of the IL-12 family
IL-12 is the strongest known inducer of IL-21 for human CD4 + T cells 13, 14 . IL-12 can also modulate CXCR5 expression 30 . Therefore, we sought to determine whether IL-12 might act in synergy with activin A. The regulation of CXCR5 expression by activin A was enhanced by IL-12 ( Fig. 3a,b) . Expression of CXCR5 and PD-1 was retained by cells stimulated for 10 d in an in vitro culture with activin A in combination with IL-12 ( Fig. 3c) . We also evaluated two additional members of the IL-12 family of cytokines: IL-23 and IL-35. IL-23 had little activity in combination with activin A, while IL-35 had no relevant effect on the expression of CXCR5 and PD-1 in serum-free conditions ( Supplementary Fig. 3c,d) .
Treatment of activated CD4 + T cells with an activin-A-neutralizing monoclonal antibody abolished the differentiation of PD-1 + CXCR5 + cells during culture with activin A at a range of concentrations ( Fig. 3d and Supplementary Fig. 3b ). Activin A binds and signals mainly through the type I receptor for activin A (ACVR1B (ALK4)) in complex with the type IIA (ACVR2A) or IIB (ACVR2B) receptor for activin A 31, 32 . A monoclonal antibody to both human type II receptors for activin A produced a substantial decrease in the induction of the expression of PD-1 and CXCR5 driven by activin A (Fig. 3d) . Thus, activin A acted directly on activated human CD4 + T cells and regulated the expression of PD-1 and CXCR5 in a manner specific to the type II receptors for activin A.
'Instruction' of a human T FH gene program by activin A
Since activin A promoted the expression of the canonical T FH cell markers PD-1 and CXCR5, we sought to determine if activin A, alone or in combination with IL-12, likewise regulated the expression of additional molecules known to be important for T FH cell biology. Activin A was sufficient to decrease the expression of CCR7 on activated CD4 + T cells ( Fig. 3e) . Moreover, a significant fraction of CD4 + T cells differentiated with activin A plus IL-12 increased their expression of Bcl6 ( Fig. 3f and Supplementary Fig. 4a,b ). Next we used RNA sequencing (RNA-seq) to ascertain the global transcriptomic profile of the T FH cell-like cells differentiated in vitro. Comparison of the gene-expression profiles of CD4 + T cells cultured in vitro and bona fide human GC T FH cells revealed that cells differentiated in presence of activin A alone or activin A plus IL-12 were 'imprinted' with the expression of bona fide GC T FH cell-signature genes (a false-discovery rate ('FDRq') value of 0.015 for cells cultured with activin A plus IL-12 versus those cultured with beads only; Fig. 3g-i) . Activin A contributed more than IL-12 did to driving expression of genes associated with GC T FH cells (P = 0.046, cells cultured with activin A plus IL-12 versus those cultured with IL-12, and P = 0.14, cells cultured with activin A plus IL-12 versus those cultured with activin A; Fig. 3h,i) . Activin A plus IL-12 resulted in the selective upregulation of 116 genes relative to their expression in cells differentiated with beads only ( Fig. 3j and Supplementary Table 1 ), including several T FH cellassociated genes, such as SLAMF1, LIF, LTA and TNF ( Fig. 3k and Supplementary Fig. 5 ), in addition to CXCR5 and PDCD1 (which encodes PD-1) ( Fig. 3j,k) . Activin A emerged as the main factor regulating LIF, LTA, PDCD1 and TNF (Fig. 3k) . We confirmed higher expression of LIF and SLAMF1 by cells differentiated with activin A plus IL-12 than by cells cultured with beads only (Fig. 3l,m) . In addition to the upregulated genes, a set of 60 genes was suppressed by activin A plus IL-12 ( Fig. 3j and Supplementary Table 2 ). Activin A caused significant downregulation of PRDM1, which encodes the transcription factor Blimp-1 ( Fig. 3k,n) . Blimp-1 is a potent and wellestablished Bcl6 antagonist that has low expression in bona fide T FH cells 1 . ITGB7, which encodes integrin β 7 and had low expression in human GC T FH cells ( Supplementary Fig. 5 ), was downregulated in the presence of activin A (Fig. 3o) . Collectively, our gene-expression analysis indicated that activin A was sufficient to regulate the expression of multiple molecules important for T FH cell biology, including those involved in migration, differentiation and proliferation.
Regulation of T FH cell function by activin A
T FH cells are defined by their specialized function as B cell helpers. To investigate whether activin A was able to modulate T FH cell function, we evaluated the production of canonical T FH cell lymphokines by cells differentiated in vitro. CXCL13, the chemokine ligand of CXCR5, exhibits cytokine-type activity when it is on the surface of B lymphocytes 33 and is one of the defining factors secreted by human T FH cells. CXCL13 is constitutively produced in large quantities by human GC T FH cells and is selectively expressed by circulating memory T FH cells when they are re-stimulated [34] [35] [36] . Activin A selectively induced the expression of CXCL13 by CD4 + T cells in vitro (Fig. 4a) .
IL-21 is a cytokine produced at high levels by GC T FH cells and circulating memory T FH cells 36, 37 . IL-21 regulates GC B cell survival and plasma-cell differentiation 4, 38 . As expected, CD4 + T cells cultured in vitro with IL-12 produced IL-21 after short re-stimulation with the phorbol ester PMA and ionomycin ( Fig. 4b) . Moreover, cells cultured with activin A plus IL-12 retained full IL-21-production potential (Fig. 4b) . CD4 + T cells cultured with activin A (alone or with IL-12) had higher expression of the cytokine TNF and lymphotoxin-α (as proteins) than that of cells cultured without activin A (beads only A r t i c l e s and IL-12) after re-stimulation ( Fig. 4c,d) , consistent with the data obtained by RNA-seq. Finally, we evaluated the ability of cells differentiated with activin A to provide help to B cells. CD4 + T cells differentiated with activin A plus IL-12 were functionally competent helpers of B cells and were able to support B cell proliferation and survival, plasmablast differentiation, and immunoglobulin G (IgG) production ( Fig. 4e) . Overall, our data indicated that activin A, in combination with IL-12, promoted the generation of T FH cell-like cells that had high expression of CXCR5 and PD-1, modulated their expression of Bcl6, PRDM1, CCR7, ITGB7 and SLAMF1, and displayed T FH cell functional properties, including B cell-helper activity and production of CXCL13, IL-21, TNF and lymphotoxin-α.
Activin A-cytokine TGF-b relationship in T FH differentiation TGF-β is a pleiotropic cytokine involved in the differentiation of various CD4 + T cell subsets in a context-dependent fashion 39 . A published npg A r t i c l e s study has shown that TGF-β, in conjunction with IL-12 and other cytokines, has a role in the differentiation of human T FH cells 12 . While activin A and TGF-β use independent receptors, both cytokines can trigger SMAD2-SMAD3 signaling pathways downstream of their respective receptors 31, 32, 39 . We used stringent serum-free conditions and found that TGF-β acted in synergy with IL-12 to induce the expression of CXCR5 and PD-1 in activated naive CD4 + T cells cultured in vitro for 5 d (Supplementary Fig. 6a ). While a T FH cell gene signature was present in the serum-free cultures, by RNA-seq analysis, a gene signature of the T H 17 subset of helper T cells 12 was not observed (data not shown). When combined with IL-12, TGF-β and activin A displayed a similar ability to regulate the differentiation of PD-1 + CXCR5 + cells and Bcl6 + cells (Supplementary Fig. 6b ).
Comparison of gene expression (by RNA-seq analysis) revealed a high degree of similarity between cells treated with activin A plus IL-12 and those treated with TGF-β plus IL-12 ( Fig. 5a,b) . Most of the genes selectively regulated by activin A plus IL-12 followed the same trend as that of genes regulated by TGF-β plus IL-12, as measured by RNA-seq analysis (Fig. 5b) . Activated CD4 + T cells are able to secrete activin A following stimulation via the T cell antigen receptor 26 . Because TGF-β mirrored activin A in driving the differentiation of human T FH cells, we explored the possibility that activin A accounted for the TGF-βinduced phenotype in vitro. However, blockade of activin A did not alter the frequency of PD-1 + CXCR5 + cells induced by TGF-β ( Fig. 5c) , which indicated that activin A was not responsible for the TGF-βinduced T FH cell differentiation. Conversely, antibody to TGF-β (anti-TGF-β) did not have any relevant effect on activin-A-mediated T FH cell differentiation (Fig. 5d,e ), which suggested that TGF-β was not responsible for the activin-A-induced T FH cell differentiation. Next we evaluated whether these two cytokines could induce the expression of PD-1 and CXCR5 in an additive or synergistic fashion. Neither PD-1 expression nor CXCR5 expression changed when activin A and TGF-β were combined in vitro (Fig. 5f,g) . Despite driving highly similar gene expression, activin A and TGF-β significantly differed in their ability to induce expression of the transcription factor Foxp3, with activin A being less potent than TGF-β in driving the generation of Foxp3 + cells (Fig. 5h,i) . Differential induction of Foxp3 might be important in vivo, since Foxp3 is the lineage-defining transcription factor of regulatory T cells. Thus, TGF-β might 'preferentially' bias cells toward a regulatory T cell phenotype, and activin A might bias cells toward a T FH cell phenotype. In summary, activin A and TGF-β did not account for each other's ability to regulate T FH cell biology, and TGF-β 'preferentially' induced Foxp3 expression.
Modulation of activin-A-mediated T FH differentiation by IL-2
We noted that PRDM1 was expressed by activated human CD4 + T cells and that PRDM1 expression was lower in activin-A-stimulated T cells than in other cells analyzed (Fig. 3j,k) . Blimp-1 is one of the strongest negative regulators of T FH differentiation, through its ability to antagonize Bcl6 and directly suppress Cxcr5 expression 1, 40 . IL-2 potently induces Blimp-1 expression in mouse CD4 + T cells [40] [41] [42] . We considered that reduced expression of Blimp-1 might occur via suppression of expression of the cytokine receptor subunit CD25 (IL-2Rα), but RNA-seq analysis revealed no difference in IL2RA expression in the presence of activin A relative to its expression in the absence of activin A (data not shown). We hypothesized that IL-2 secreted by CD4 + T cells might have been inhibiting the induction of T FH differentiation by activin A. Therefore, we evaluated the effect of IL-2 blockade on activin-A-treated CD4 + T cells. In the presence of activin A alone, the differentiation of PD-1 + CXCR5 + cells was largely increased when IL-2 was neutralized ( Fig. 6) . Blockade of IL-2 also modestly potentiated the expression of PD-1 and CXCR5 in cells cultured with activin A plus IL-12 (Supplementary Fig. 7) . Thus, IL-2 was a potent inhibitor of the differentiation of human T FH cells, and activin A was able to directly induce the expression of human T FH cell-associated genes in the absence of any additional cytokines.
Evolutionary requirement for activin A in T FH cell differentiation
To assess the functional conservation of activin A in T FH cell differentiation, we activated naive mouse CD4 + T cells in the presence of activin A, alone or in combination with IL-12. The amino acid sequence of activin A is 100% conserved in humans and mice. Strikingly, activin A did not have any effect on the expression of PD-1 a c b and CXCR5 by mouse CD4 + T cells (Fig. 7a,b) . This was true for both the C57BL/6 mouse strain and the BALB/c mouse strain (Fig. 7a,b) . The presence of IL-6, a known regulator of early differentiation of mouse T FH cells in vivo, in combination with activin A did not promote the in vitro differentiation of mouse T FH cells (Fig. 7b) . The lack of any measurable effect of activin A on the expression of T FH cell-associated genes by mouse CD4 + T cells prompted us to investigate whether the role of activin A in T FH differentiation was unique to humans. Thus, we evaluated the ability of activin A to drive T FH differentiation in vitro with cells from a species of a different taxonomical family, Macaca mulatta (rhesus macaques), of the non-human primate family Cercopithecidae. Potent induction of PD-1 + CXCR5 + cells was observed by activated naive M. mulatta CD4 + T cells in response to activin A (Fig. 7c,d) . These data indicated that the T FH cell-like differentiation mediated by activin A in vitro was not preserved in mice but was conserved in nonhuman primate species and humans. This finding suggested the existence of a possible evolutionary divergence in activin-A-mediated T FH cell differentiation.
SMAD2-SMAD3 pathway in activin A-induced T FH cell differentiation
SMAD2-SMAD3 is the canonical signaling pathway activated downstream of activin A's binding to type IIA and/or IIB receptors and the type I receptor ACVR1B (ALK4) 31, 32 . Phosphorylation of SMAD2-SMAD3 occurred in naive human CD4 + T cells in response to activin A (Fig. 8a,b) . Potential SMAD-independent pathways downstream of activin A were not detected, as measured by lack of phosphorylation of the mitogen-activated protein kinases p38 and ERK at the time points analyzed (Supplementary Fig. 8) . Therefore, we hypothesized that activation of SMAD2-SMAD3 was a central signaling pathway 
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A r t i c l e s in the activin-A-mediated induction of the expression of T FH cellassociated genes. Treatment with SB431542, a pharmacological inhibitor of ALK4 known to suppress the activation of SMAD2-SMAD3 but not that of the SMAD-independent pathways 43 , resulted in the complete inhibition of activin-A-mediated phosphorylation of SMAD2-SMAD3 (Fig. 8a,b) . Furthermore, the inhibition of ALK4 by SB431542 blocked the differentiation of PD-1 + CXCR5 + cells in culture conditions that included activin A (Fig. 8c,d) . Galunisertib is a SB431542-independent small-molecule inhibitor of ALK4 currently in clinical trials 44 . Galunisertib potently suppressed the generation of PD-1 + CXCR5 + cells in response to activin A ( Fig. 8e  and Supplementary Fig. 8c ). Collectively, these data pointed to A r t i c l e s SMAD2-SMAD3 as an important signaling pathway downstream of activin A in the regulation of human T FH cell differentiation. Activin A is expressed in human lymphoid tissue in both the T cell area and the T cell-B cell border area. We observed a gradient in the induction of phosphorylated SMAD2-SMAD3 by activin A in tonsillar CD4 + T cells, with naive CD4 + T cells having the greatest responsiveness to activin A (Fig. 8f,g) . PD-1 int CXCR5 int CD4 + T cells, a heterogeneous population of T FH cell-associated cells located at the T cell-B cell border and in the follicular mantle (mantle T FH cells), also induced the phosphorylation of SMAD proteins in response to activin A, although to a lesser extent than such induction by naive CD4 + T cells (Fig. 8f,g) . This reduced responsiveness might be explained at least in part by a trend of lower expression of the type I and II receptors for activin A in differentiated T FH cells than in naive CD4 + T cells (Supplementary Fig. 8d ). The tonsillar expression pattern of receptors for activin A was consistent with the finding that naive CD4 + T cells from blood expressed the genes encoding type I and type II receptors for activin A, but that following stimulation of the T cell antigen receptor, expression of these genes was downregulated (Fig. 8h) . The presence of activin A did not influence the reduction in the expression of type I and II receptors for activin A driven by triggering via the T cell antigen receptor (Fig. 8i) . In summary, activin A was expressed by myeloid cells in areas in which T FH cell differentiation is initiated, and CD4 + T cells in those locations were responsive to activin A signaling, consistent with an in vivo role for activin A as an early regulator of human T FH cell differentiation.
DISCUSSION
Our work has established a role for activin A in the differentiation of human T FH cells. Proper localization is a key feature of T FH cell biology. Activin A acted by dampening expression of CCR7 and integrin β 7 while fostering the expression of CXCR5. In addition to regulating localization, activin A also modulated the expression of regulators of T FH cell function. Activin A promoted the production of CXCL13, TNF, the cytokine LIF and lymphotoxin-α. TNF can act as co-stimulatory signal to mediate B cell activation and immunoglobulin production 38 . The roles of LIF and lymphotoxin-α in the provision of help to B cell have not been formally addressed. However, B cell hyperplasia and polyclonal hypergammaglobulinemia are found in mice that overexpress LIF 45 . In T cell-B cell co-cultures, the B cell-helper activity of the in vitro differentiated T FH cells was driven by IL-12. This assay has major limitations in that it relies mainly on the ligand for CD40 (which is expressed similarly by all activated CD4 + T cells in vitro) and IL-21. Therefore, T FH cell features regulated by activin A that are vital for B cell-helper function in vivo, such as CXCL13 and cell migration (CXCR5 and CCR7) are not emphasized in the available assay.
One important open question is whether the physiological distribution of activin A and TGF-β indicates which of these two cytokines is more relevant for T FH differentiation in vivo. There are many means by which the bioavailability of TGF-β in vivo is regulated, including the physiological activation of TGF-β in an extremely localized fashion by integrin-expressing cells 39 . The bioavailability of activin A is also regulated 31, 32 . Therefore, it is not currently possible to predict whether activin A or TGF-β is dominant in inducing T FH differentiation in a particular in vivo context. Clearly, activin A is present in human lymphoid tissue and is induced in myeloid cells by inflammatory ligands for Toll-like receptor. It is still controversial whether the acquisition of Foxp3 expression in vitro by human CD4 + T cells confers on them with the ability to suppress immune responses 46 . Nevertheless, less induction of Foxp3 expression by activin A than by TGF-β would seem to be a favorable event when the ultimate goal is the induction of human T FH cells.
Activin A alone was sufficient for the regulation of many T FH cell signature molecules, particularly in the absence of high concentrations of IL-2. Nevertheless, the integration of activin A and IL-12-mediated signals was required for the acquisition of a more complete phenotype, including high expression of IL-21. Such findings support a working model in which activin A is at the center of a cytokine network that orchestrates the differentiation of human T FH cells. This cytokine network includes not only agonistic participants, such as IL-12, but also antagonistic signals, such as IL-2. We envision the cytokine network that drives T FH differentiation to be more complex than what has been described so far.
A substantial limitation in the use of rodent models results from the evolutionary divergence in pathways shaping T FH cell biology. Fully mature mouse T FH cells and human T FH cells express an almost identical set of signature molecules. Despite the phenotypical similarity of these cells, a growing body of evidence suggests that there are signaling pathways crucial to human T FH cell differentiation that are not crucial to mouse T FH cell differentiation. Three studies have reported different outcomes on the differentiation of mouse T FH cells when TGF-β signaling was impaired. One study found that TGF-β is a positive regulator of T FH cell biology by virtue of its ability to insulate CD4 + T cells from IL-2 signaling and suppress differentiation into the T H 1 subset of helper T cells 47 . A second study, however, found no effect on T FH cells when TGF-β signaling was blocked 48 . Finally, a third study indicated that TGF-β acts as an inhibitor of T FH cells 49 . Additional studies are therefore needed to clarify TGF-β's role in T FH cell biology in mice. While we did not find any relevant effect of activin A on mouse CD4 + T cells in vitro, activin A potently induced the differentiation of human and non-human primate T FH cells. These data would suggest the existence of a potential evolutionary divergence in the role of activin A in T FH cell biology. Alternatively, the inability of activin A to induce the differentiation of mouse CD4 + T cells into T FH cells in vitro might reflect an unknown inhibitor or cofactor.
It is highly desirable to increase T FH cells in vivo for vaccines when the generation of a protective vaccine relies on the production of neutralizing antibodies 1 . Memory T FH cells and recently activated T FH cell-related cells can be found in blood 1, 7, [35] [36] [37] 50 . Highly functional memory T FH cells are the strongest immunological correlate for the development of broadly neutralizing antibodies to human immunodeficiency virus in donors positive for this virus 36 . In contrast, dysregulated antibody responses might lead to autoantibody-mediated diseases 3, 7 , and memory T FH cells are altered in rheumatoid arthritis, systemic lupus erythematous and juvenile dermatomyositis 3, 7, 37 . In these contexts, hampering T FH cells in a targeted fashion represents a promising therapeutic approach. An appealing candidate might be galunisertib 44 , which is currently being tested in clinical trials. In conclusion, our study has revealed a powerful approach for the identification of previously unknown regulators of human T FH cell differentiation, which led to the discovery of activin A as potent regulator of such differentiation.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: RNA-seq data, GSE78276.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. npg activin A. Supernatants were diluited 1:20 and activin A was measured by a Human/Mouse/Rat activin A Quantikine ELISA kit (R&D) following the manufacturer's instructions.
T cell-B cell co-culture. Naive CD4 + T cells were differentiated with activin A and/or IL-12. At day 3, live CD4 + T cells were sorted by flow cytometry. Fresh autologous B cells were enriched from PBMCs by CD19 magneticbead positive selection (Miltenyi Biotec). Memory B cells were then sorted by flow cytometry as CD3 − CD14 − CD4 − CD19 + IgD − CD27 + cells as previously described 36 and cultured (4 × 10 5 cells/well) with the in vitro-differentiated T cells (2.5 × 10 3 cells/well) in the presence of staphylococcal enterotoxin B (0.25 ng/ml, Toxin Technology) in AIM-V medium. B cell counts and plasmablast frequencies were measured after 7 d by flow cytometry as previously described 36 . Immunoglobulin concentrations in the supernatants were determined by ELISA.
Mouse CD4 + T cell differentiation. Naive CD4 + T cells were isolated from spleen using the Naive CD4 + T cell isolation kit (Stem Cell). Purity was 92% or higher. Naive CD4 + T cells (2 × 10 5 cells/well) were cultured for 3 d with recombinant human-mouse-rat activin A (50 ng/ml, R&D Systems), recombinant mouse IL-12 (10 ng/ml, Peprotech), and/or recombinant mouse IL-6 (20 ng/ml, Peprotech) in the presence of plate-bound monoclonal antibody to mouse CD3 (8 µg/ml, clone 145-2C11, BioXcell) and anti-mouse-CD28 (8 µg/ml, clone 37.51, BioXcell), in RPMI medium, supplemented with 10% FBS, GlutaMAX, penicillin-streptomycin, and 2.5 µM β-mercaptoethanol. After 3 d, cells were removed from stimuli and further cultured for 2 additional d in IL-2 (50 U/ml,) and the same cytokine combination used at day 0. Phenotype was quantified by flow cytometry (antibodies, Supplementary  Table 3 ) at day 5 of the in vitro culture.
Non-human primate CD4 + T differentiation. CD4 + T cells from rhesus macaque PBMCs were enriched using the Non-Human Primate CD4 + T Cell Isolation Kit (Miltenyi Biotec). Naive CD4 + T cells were isolated by flow cytometry as CD4 + CD45RA + CD95 − CD28 + CCR7 + cells. Naive CD4 + T cells (7.5 × 10 4 cells/well) were activated by plate-bound anti-human-CD3 (clone SP34) and anti-human-CD28 (clone CD28.2) (both at 5 µg/ml, BD) and cultured with recombinant human-mouse-rat activin A (50 ng/ml) and/or recombinant human IL-12 (5 ng/ml) for 5 d. Phenotype was assessed by flow cytometry with the staining panel in Supplementary Table 3. RNA sequencing. The differentiation of naive CD4 + T cells with activin A and/or IL-12 was as described above. Naive CD4 + T cells from four or more donors were cultured with the following conditions: beads only, IL-12, activin A (100 ng/ml), activin A (100 ng/ml) plus IL-12, TGF-β, or TGF-β plus IL-12. After 3 d of in vitro culture, live CD4 + T cells were sorted by flow cytometry. Total RNA was purified using miRNAeasy Mini kit (Qiagen). Standard quality control steps were included to determine total RNA quality using Agilent Bioanalyzer (RNA integrity number (RIN) > 8.5; Agilent RNA 6000 Nano Kit) and quantity using a nanoliter spectrophotometer (Nanodrop, Thermofisher). For every sample, 500 ng of purified total RNA was prepared into mRNA libraries, according to manufacturer's instructions, using the Truseq Stranded mRNA Library Prep Kit (Illumina, RS-122-2103). The resulting libraries were deep sequenced, using the Illumina HiSeq2500 system in rapid run mode, to obtain between 6 × 10 6 and 7 × 10 6 of 50-bp length single-end reads per library ( Supplementary Table 5 ).
